CAMBRIDGE, MA—Stephen Hoge, President of Moderna , Inc. (NASDAQ:MRNA), recently executed stock transactions as detailed in a Form 4 filing with the SEC. On December 3, Hoge sold 314 shares of the company's common stock at an average price of $43.30 per share, amounting to a total sale value of $13,595. The transaction comes as Moderna's stock has experienced significant volatility, with shares down over 70% in the past six months, according to InvestingPro data. This transaction was part of a mandatory "sell to cover" to satisfy tax obligations related to the vesting of restricted stock units (RSUs).
Following these transactions, Hoge holds 1,443,904 shares directly. Additionally, he maintains indirect ownership of shares through a trust and other entities, including 4,116 shares by Valhalla, LLC, and 151,933 shares by a trust for his family's benefit.
These transactions are part of routine financial management and do not reflect discretionary trading by Hoge. For deeper insights into insider trading patterns and comprehensive analysis of Moderna's financial health, including 13 additional ProTips and detailed metrics, visit InvestingPro.
In other recent news, Moderna's Phase 3 CMVictory study on cytomegalovirus (CMV) has been met with skepticism by Leerink Partners, who maintained their Underperform rating on the company. This follows recent financial reporting, where Moderna announced third-quarter revenues of $1.9 billion and a net income of $13 million. Despite these figures, Berenberg has expressed concerns about Moderna's ability to achieve its medium-term financial goals, primarily due to challenges within its respiratory vaccine franchise and high expenditure on research and development.
Moderna's mRESVIA vaccine has recently received approval in Canada, marking a significant milestone for the company. This follows similar authorizations in the United States, Europe, and Qatar. Analyst firms Berenberg, Piper Sandler, and TD Cowen have provided their perspectives on Moderna's stock, with Berenberg and TD Cowen initiating a Hold rating and Piper Sandler maintaining an Overweight rating despite lowering its price target.
Moderna has revealed plans to release eight new vaccines by 2028, a move that analysts from Piper Sandler anticipate will boost sales after a projected low in 2025. Additionally, the company intends to purchase its Norwood campus for $400 million and awaits multiple vaccine approvals in the coming years. These recent developments highlight the ongoing progress and potential for growth at Moderna.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.